phrykt

Solid Biosciences Inc. (SLDB): who owns it and who trades it

As of Nov 16, 2026, SLDB insiders reported 27 open-market sales worth $2.7M and no purchases in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alexander Cumbo (CEO), with $984K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Solid Biosciences

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SLDB

156 funds and institutions reported SLDB shares worth $1.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 12.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Ra Capital Management, L.P.12.2%
Perceptive Advisors LLC12.1%
Bain Capital Life Sciences Investors, LLC10.0%
Siren, L.L.C.7.8%
BlackRock, Inc.7.0%
FMR LLC (Fidelity)7.0%
Armistice Capital, LLC4.3%
State Street Corp4.2%
Jupiter Topco LLC4.1%
Vanguard Capital Management LLC4.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.12.04M12.23%$120M+29%
Perceptive Advisors LLC11.91M12.10%$119MNo change
Bain Capital Life Sciences Investors, LLC9.81M9.97%$98MNo change
Siren, L.L.C.7.69M7.82%$76.8MNo change
BlackRock, Inc.6.93M7.05%$69.3M+40%
FMR LLC (Fidelity)6.88M6.99%$68.7M+91%
Armistice Capital, LLC4.28M4.35%$42.7M+34%
State Street Corp4.18M4.24%$41.7M+271%
Jupiter Topco LLC4.04M4.11%$40.4M–
Vanguard Capital Management LLC4.01M4.08%$40.1M+50%
Rtw Investments, LP3.89M3.96%$38.9M–
Deep Track Capital, LP3.57M3.62%$35.6MNo change
Franklin Resources Inc3.44M3.50%$34.4M+57%
Citadel Advisors LLC2.82M2.86%$28.1M+8%
Alyeska Investment Group, L.P.2.28M2.32%$22.8MNo change
Ameriprise Financial Inc2.23M2.26%$22.2M-9%
Vestal Point Capital, LP2.16M2.20%$21.6M-57%
Redmile Group, LLC1.95M1.98%$19.5M-3%
Geode Capital Management, LLC1.94M1.97%$19.4M+50%
Goldman Sachs Group Inc1.60M1.63%$16M+71%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SLDB insiders reported $0 of open-market purchases and $2.7M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.7M
27 trades, 7 people
Sales under a 10b5-1 plan
1%
Share of sale value
Latest trade
Oct 19, 2026
Filed Oct 20, 2026

Purchases and sales by month

$2.5M$2.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 19, 2026Gabriel BrooksChief Medical OfficerSale plan4,374$5.62$24.6KForm 4
Feb 18, 2026Alexander CumboCEOSale16,644$5.82$96.9KForm 4
Feb 18, 2026Jessie HanrahanChief Regulatory OfficerSale4,134$5.82$24.1KForm 4
Feb 18, 2026Ilan GanotDirectorSale2,658$5.82$15.5KForm 4
Feb 18, 2026Paul HerzichChief Technology OfficerSale3,616$5.82$21KForm 4
Feb 18, 2026David T HowtonChief Operating OfficerSale7,469$5.82$43.5KForm 4
Feb 18, 2026Kevin TanCFOSale5,404$5.82$31.5KForm 4
Feb 4, 2026David T HowtonChief Operating OfficerSale18,894$6.44$122KForm 4
Feb 4, 2026Alexander CumboCEOSale48,913$6.44$315KForm 4
Feb 4, 2026Ilan GanotDirectorSale7,205$6.44$46.4KForm 4
Feb 4, 2026Kevin TanCFOSale14,783$6.44$95.2KForm 4
Feb 4, 2026Gabriel BrooksChief Medical OfficerSale12,616$6.44$81.2KForm 4
Feb 4, 2026Jessie HanrahanChief Regulatory OfficerSale12,348$6.44$79.5KForm 4
Feb 4, 2026Paul HerzichChief Technology OfficerSale10,905$6.44$70.2KForm 4
Feb 2, 2026Kevin TanCFOSale26,837$6.44$173KForm 4
Feb 2, 2026Alexander CumboCEOSale80,258$6.44$517KForm 4
Feb 2, 2026Jessie HanrahanChief Regulatory OfficerSale26,535$6.44$171KForm 4
Feb 2, 2026Gabriel BrooksChief Medical OfficerSale28,335$6.44$182KForm 4
Feb 2, 2026David T HowtonChief Operating OfficerSale37,771$6.44$243KForm 4
Feb 2, 2026Paul HerzichChief Technology OfficerSale26,250$6.44$169KForm 4
Jan 28, 2026Ilan GanotDirectorSale191$6.59$1.3KForm 4
Jan 13, 2026Kevin TanCFOSale5,704$5.27$30.1KForm 4
Jan 5, 2026Ilan GanotDirectorSale1,053$5.43$5.7KForm 4
Dec 3, 2025David T HowtonChief Operating OfficerSale4,932$5.11$25.2KForm 4
Dec 3, 2025Alexander CumboCEOSale10,808$5.11$55.2KForm 4
Dec 3, 2025Jessie HanrahanChief Regulatory OfficerSale4,483$5.11$22.9KForm 4
Dec 3, 2025Paul HerzichChief Technology OfficerSale2,701$5.11$13.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alexander CumboPresident and CEO, Director–$984KFeb 18, 2026
David T HowtonChief Operating Officer–$434KFeb 18, 2026
Kevin TanCFO & Treasurer–$330KFeb 18, 2026
Jessie HanrahanChief Regulatory Officer–$297KFeb 18, 2026
Gabriel BrooksChief Medical Officer–$288KOct 19, 2026
Paul HerzichChief Technology Officer–$274KFeb 18, 2026
Ilan GanotDirector–$68.8KFeb 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SLDB short interest

High short interest. 11.9% of SLDB shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 46%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 13.30M SLDB shares were sold short, 11.9% of the shares outstanding, up 8.2% from the report before. At the average daily volume of 1.24M shares, buying them all back would take about 10.7 trading days (days to cover).

Shares short, % of all shares

11.9%May 15Oct 3020.0%

Days to cover

10.7May 15Oct 3021.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202613.30M11.92%+8%1.24M10.7
Oct 15, 202612.30M11.47%-3%1.44M8.5
Sep 30, 202612.73M11.87%-26%1.66M7.7
Sep 15, 202617.11M15.95%+4%871,45319.6
Aug 31, 202616.38M15.28%-1%866,30318.9
Aug 14, 202616.62M15.50%-2%847,63819.6
Jul 31, 202617.04M17.31%-4%1.05M16.2
Jul 15, 202617.67M17.96%-3%1.58M11.2
Jun 30, 202618.27M18.57%+57%4.00M4.6
Jun 15, 202611.61M11.80%+21%1.31M8.8
May 29, 20269.60M9.76%+5%1.02M9.4
May 15, 20269.10M9.25%+3%1.33M6.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Solid Biosciences company events

Solid Biosciences filed 5 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Aug 6, 2026.

  1. Aug 6, 2026AnnouncementSolid Biosciences Inc. filed a prospectus supplement under the Company’s universal shelf registration statement on Form S-3 (File No. 333-287325) that was originally filed with the Securities and Exchange Commission on May 15, 2025 and was declared effective by the SEC on May 27, 2025, relating to… Filing
  2. Jun 10, 2026VoteReported shareholder vote results. Filing
  3. Apr 10, 2026LeadershipFor the sole purpose of achieving an equal balance of membership among the three classes of the Board of Directors of Solid Biosciences Inc., effective at 4:00 p.m., Eastern Time, on April 10, 2026, Ilan Ganot, a member of the Board who was serving in Class III (which class will be up for election… Filing
  4. Mar 12, 2026AnnouncementThe Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy… Filing
  5. Mar 6, 2026AgreementSolid Biosciences Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold SLDB

4 of the 50 well-known investors we track reported holding SLDB in their latest 13F filing. The largest position is Ken Griffin's, worth $15.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.10M$15.2M0.0%-26%
Israel Englander · Millennium ManagementQ3 2026237,633$1.7M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 2026104,314$754K0.0%+1%
Steve Cohen · Point72 Asset ManagementQ3 2026100,471$726K0.0%-78%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SLDB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026RTW Investments, LP13G5.5%
Nov 16, 2026RTW Investments, LP13G5.5%
Nov 6, 2026RA Capital Management, L.P.13D/A10.8%
Nov 6, 2026RA Capital Management, L.P.13D/A10.8%

Questions about Solid Biosciences Inc. (SLDB) stock

Who owns the most SLDB stock?

The largest reported owner of Solid Biosciences Inc. (SLDB) is Ra Capital Management, L.P., with 12.2% of the company. In total, 156 funds and institutions reported holding SLDB at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SLDB insiders buying or selling?

In the last 12 months, SLDB insiders reported no open-market purchases and 27 sales worth $2.7M. The latest trade was on Oct 19, 2026. See every trade.

What is the short interest in SLDB?

As of Oct 30, 2026, 13.30M SLDB shares were sold short, 11.9% of the shares outstanding, up 8.2% from the report before. At the average daily volume of 1.24M shares, buying them all back would take about 10.7 trading days (days to cover). See the history.

Which famous investors hold SLDB?

4 of the 50 well-known investors we track reported SLDB in their latest 13F filing, including Ken Griffin, Israel Englander, Ken Fisher. The largest position is worth $15.2M. See all holders.

Executive pay

Solid Biosciences's chief executive was paid a total of $5.2M for the year ended Dec 31, 2025, up 7% from $4.9M the year before. In the last 12 months, Solid Biosciences's executives and directors bought no stock on the open market and sold $2.7M.

Chief executive, total pay$5.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.